Search results for "stroke."

showing 10 items of 1178 documents

Exercise stress CMR reveals reduced aortic distensibility and impaired right-ventricular adaptation to exercise in patients with repaired tetralogy o…

2018

International audience; The aim of our study was to evaluate the feasibility of exercise cardiac magnetic resonance (CMR) in patients with repaired tetralogy of Fallot (RTOF) and to assess right and left ventricular adaptation and aortic wall response to exercise in comparison with volunteers.Methods11 RTOF and 11 volunteers underwent prospective CMR at rest and during exercise. A supine bicycle ergometer was employed to reach twice the resting heart rate during continuous exercise, blood pressure and heart rate were recorded. Bi-ventricular parameters and aortic stiffness were assessed using accelerated cine sequences and flow-encoding CMR. A t-test was used to compare values between group…

MalePhysical-ExerciseVentricular Dysfunction RightBlood PressureVascular MedicineVentricular Dysfunction Left[SPI]Engineering Sciences [physics]Heart RateMedicine and Health SciencesPublic and Occupational HealthProspective StudiesCardiac OutputMaterialsAortaTreadmillQRHeartRegurgitationMagnetic Resonance ImagingSports SciencePulmonary Valve-ReplacementPhysical SciencesTetralogy of FallotMagnetscardiovascular systemMedicineFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringAnatomyResearch ArticleAdultCardiac VentriclesScienceHeart VentriclesRestMaterials ScienceCardiologyStress PhysiologicalAscending AortaHumansSports and Exercise MedicineExerciseCardiac MriHemodynamicsBiology and Life SciencesStroke VolumePhysical ActivityElasticityPhysical FitnessCongenital Heart-DiseaseExercise TestCardiovascular AnatomyRate-Pressure ProductFeasibility StudiesBlood VesselsArterial Stiffness
researchProduct

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

2021

BackgroundCirculating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.MethodsConsecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.ResultssNEP was measure…

MalePhysiologyCancer TreatmentCardiovascular MedicineBiochemistrySacubitrilMedical ConditionsClinical endpointMedicine and Health SciencesMultidisciplinaryEjection fractionPharmaceuticsAminobutyratesHazard ratioQRMiddle AgedPrognosisBody FluidsCardiovascular TherapyBloodValsartanOncologyCardiovascular DiseasesCardiologycardiovascular systemMedicineValsartanFemaleNeprilysinAnatomymedicine.drugcirculatory and respiratory physiologyResearch Articlemedicine.medical_specialtyScienceCardiologyDrug TherapyInternal medicinemedicineHumanscardiovascular diseasesAgedProportional Hazards ModelsHeart FailureProportional hazards modelbusiness.industryBiphenyl CompoundsBiology and Life SciencesStroke VolumeCardiovascular Disease Riskmedicine.diseaseHeart failurebusinessSacubitril ValsartanBiomarkersReceptor Antagonist TherapyEjection FractionPloS one
researchProduct

Epidemiology of stroke in Europe and trends for the 21st century

2016

International audience; Despite major improvements in primary prevention and acute treatment over the last decades, stroke is still a devastating disease. At the beginning of the 21st century, the age-standardized incidence of stroke in Europe ranged from 95 to 290/100,000 per year, with one-month case-fatality rates ranging from 13 to 35%. Approximately 1.1 million inhabitants of Europe suffered a stroke each year, and ischemic stroke accounted for approximately 80% of cases. Although global stroke incidence is declining, rates observed in young adults are on the rise, thus suggesting a need for strategies to improve prevention. In addition, because of the ageing population, the absolute n…

MalePopulation ageingPediatricsmedicine.medical_specialtyLacunar strokeDijonDisease030204 cardiovascular system & hematologyLacunar stroke03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAcute careEpidemiologymedicineHumans30-day case-fatalityRecurrent strokeTransient ischemic attackStrokeAtrial-fibrillationDepression (differential diagnoses)business.industryIncidenceIncidence (epidemiology)General Medicine[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthEuropeStrokeRisk-factorsCognitive impairmentPopulation registryFemalebusiness030217 neurology & neurosurgeryDemography
researchProduct

Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke

2011

T lymphocytes are increasingly recognized as key modulators of detrimental inflammatory cascades in acute ischaemic stroke, but the potential of T cell-targeted therapy in brain ischaemia is largely unexplored. Here, we characterize the effect of inhibiting leukocyte very late antigen-4 and endothelial vascular cell adhesion molecule-1-mediated brain invasion-currently the most effective strategy in primary neuroinflammatory brain disease in murine ischaemic stroke models. Very late antigen-4 blockade by monoclonal antibodies improved outcome in models of moderate stroke lesions by inhibiting cerebral leukocyte invasion and neurotoxic cytokine production without increasing the susceptibilit…

MalePore Forming Cytotoxic ProteinsIntegrin alpha4medicine.medical_treatmentT cellVascular Cell Adhesion Molecule-1Enzyme-Linked Immunosorbent AssayInflammationBrain ischemiaInterferon-gammaMicechemistry.chemical_compoundCell MovementLeukocytesAnimalsCytotoxic T cellMedicineLymphocytesVCAM-1Cell adhesionGait Disorders NeurologicNeuroinflammationMice KnockoutPerforinbusiness.industryAntibodies MonoclonalBrainFlow Cytometrymedicine.diseaseUp-RegulationDNA-Binding ProteinsMice Inbred C57BLStrokeDisease Models AnimalCytokinemedicine.anatomical_structurechemistryImmunologyEncephalitisNeurology (clinical)medicine.symptombusinessBrain
researchProduct

Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk

2015

Abstract— Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with min…

MalePredictive Value of TestAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzimidazoleBenzoatesRamiprilRetrospective StudieHeart RateRisk FactorsCardiovascular DiseaseTelmisartanCognitive declineMultivariate AnalysiRandomized Controlled Trials as TopicAged 80 and overmedicine.diagnostic_testIncidenceMiddle AgedstrokeAntihypertensive Agentmyocardial infarctionCardiovascular DiseasesHypertensionCardiologyDrug Therapy CombinationFemaleHumanmedicine.drugRamiprilmedicine.medical_specialtyBenzoateFollow-Up StudieCognition DisorderPredictive Value of TestsInternal medicineHeart rateInternal MedicinemedicineHumansDementiaAntihypertensive AgentsAgedRetrospective StudiesMini–Mental State Examinationbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratiomedicine.diseaseConfidence intervalBlood pressureMultivariate AnalysisPhysical therapyBenzimidazolesCognition DisordersbusinessFollow-Up StudiesHypertension
researchProduct

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The …

2010

Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. R…

MalePrognosiIncidenceRisk FactorReproducibility of ResultRisk AssessmentFollow-Up StudieEuropeStrokeRetrospective StudiePopulation SurveillanceThromboembolismAtrial FibrillationFemaleAgedHuman
researchProduct

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

2021

Background: Aspiration community-acquired pneumonia (ACAP) and community-acquired pneumonia (CAP) in patients with aspiration risk factors (AspRFs) are infections associated with anaerobes, but limited evidence suggests their pathogenic role. Research Question: What are the aspiration risk factors, microbiology patterns, and empiric anti-anaerobic use in patients hospitalized with CAP? Study Design and Methods: This is a secondary analysis of GLIMP, an international, multicenter, point-prevalence study of adults hospitalized with CAP. Patients were stratified into three groups: (1) ACAP, (2) CAP/AspRF+ (CAP with AspRF), and (3) CAP/AspRF- (CAP without AspRF). Data on demographics, comorbidi…

MalePulmonary and Respiratory Medicinemedicine.drug_classAspiration riskAntibioticsNursing home residentSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineMicrobiologyanaerobic; aspiration; bacteria; pneumonia; risk factors.Cohort Studies03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaTaverneAnti-Bacterial AgentmedicineHumanspneumoniarisk factors.Community-Acquired Infection030212 general & internal medicinebacteriaStrokeAgedAged 80 and overaspirationbusiness.industryRespiratory AspirationMiddle Agedmedicine.diseaseAntibiotic coverageAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumonia030228 respiratory systemRisk factorsrisk factoranaerobicFemaleUnderweightmedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

Diagnosis of perioperative myocardial necrosis following coronary artery surgery — a reappraisal of isoenzyme analysis

1990

Although the routine determination of CK-MB activity is widely used after coronary artery bypass grafting (CABG), the diagnosis of a perioperative myocardial necrosis remains arbitrary. The intention of the present study was to develop discriminative enzymatic parameters of CK-MB activity in a collective of 710 patients following CABG. Patients were grouped according to their postoperative electrocardiogram (ECG). For each patient, the time activity curve of CK-MB was determined. The total amount of CK-MB was calculated by integrating the area beneath the CK-MB activity curve. Patients presenting with an unchanged postoperative ECG (group I) or a new bundle branch block with uncompromised h…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPercentileCardiac outputMyocardial InfarctionHemodynamicsElectrocardiographyInternal medicinemedicineHumansDerivationCoronary Artery BypassIntraoperative ComplicationsCreatine KinaseBundle branch blockbiologybusiness.industryHemodynamicsStroke VolumeGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseIsoenzymesmedicine.anatomical_structureAnesthesiaCardiologybiology.proteinFemaleSurgeryCreatine kinaseCardiology and Cardiovascular MedicinebusinessArteryEuropean Journal of Cardio-Thoracic Surgery
researchProduct

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

2017

Background The risk and outcomes of stroke in patients with chronic obstructive pulmonary disease exacerbations (COPDe) remain unclear. We examined whether patients with COPDe faced increased risk of stroke or post-stroke outcomes. Methods Using Taiwan’s National Health Insurance Research Database, we identified 1918 adults with COPDe and selected comparison cohorts of 3836 adults with COPD no exacerbations and 7672 adults without COPD who were frequency matched by age and sex in 2000–2008 (Study 1). Stroke event was identified during 2000–2013 follow-up period. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of stroke associated with COPDe were calculated. In a nested cohor…

MalePulmonologyEconomicslcsh:MedicineSocial SciencesComorbidityVascular MedicinePulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMedicine and Health SciencesOdds Ratio030212 general & internal medicinelcsh:ScienceStrokeAged 80 and overCOPDMultidisciplinaryHazard ratioMiddle AgedStrokeHospitalizationNeurologyResearch DesignPopulation SurveillanceDisease ProgressionFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignChronic Obstructive Pulmonary DiseaseCerebrovascular DiseasesCardiologyTaiwanResearch and Analysis MethodsRisk Assessment03 medical and health sciencesHealth EconomicsInternal medicinemedicineHumansIntensive care medicineAdverse effectIschemic StrokeAgedRetrospective StudiesEpilepsybusiness.industrylcsh:RRetrospective cohort studyOdds ratioPneumoniamedicine.diseaseComorbidityrespiratory tract diseasesHealth CarePatient Outcome Assessment030228 respiratory systemlcsh:QAdverse EventsbusinessHealth InsurancePLoS ONE
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct